BioNTech to co-develop mRNA immunotherapy with Sanofi

BioNTech SE (Mainz, Germany) exercised an option under a 2015 deal to co-develop with Sanofi (Euronext:SAN; NASDAQ:SNY) an mRNA-based immunotherapy. Sanofi will make an €80 million ($91.5 million) equity investment in BioNTech.

BioNTech said the product is entering clinical testing in multiple solid tumors. A company spokesperson told BioCentury that the immunotherapy's mRNAs encode a set of cytokines to stimulate the immune system, but did not provide details on the underlying targets or development timeline...